Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 9, 2013

Primary Completion Date

December 6, 2016

Study Completion Date

December 6, 2016

Conditions
Kidney Transplant
Interventions
DRUG

Belatacept

Single intravenous infusion of belatacept, 7.5 mg/kg

Trial Locations (8)

20010

Childrens National Medical Center, Washington D.C.

30322

Emory University, Atlanta

35233

University Of Alabama At Birmingham, Birmingham

63110

Washington University, St Louis

90027

Childrens Hospital Of La, Los Angeles

90095

University Of California Los Angeles, Los Angeles

94305

Stanford University Medical Center, Stanford

02115

Boston Childrens Hospital, Boston

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY